Dr. Patrick W. Cobb, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
1315 Golden Valley Cir
Billings, MT 59102
Who else practices at this address →
Yellowstone County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 415
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
MT license 7719 · WY license 5703A
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 415
- Services billed
- 2,154
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 742 | 216 |
| Established patient office or other outpatient visit, 20-29 minutes | 362 | 200 |
| Established patient office or other outpatient visit, 40-54 minutes | 78 | 55 |
| Telephone medical discussion with physician, 5-10 minutes | 53 | 30 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 39 | 12 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 24 | 22 |
| New patient office or other outpatient visit, 45-59 minutes | 23 | 23 |
| Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | 21 | 13 |
| Telephone medical discussion with physician, 11-20 minutes | 17 | 14 |
| New patient office or other outpatient visit, 60-74 minutes | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 16 payments worth $15,155 in total to this clinician.
| Genentech USA, Inc. | $14,237 |
|---|---|
| Eli Lilly and Company | $800 |
| Genentech, Inc. | $118 |
| Consulting Fee | $13,369 |
|---|---|
| Travel and Lodging | $1,029 |
| Food and Beverage | $758 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech USA, Inc. Aug 20, 2025 | Consulting Fee Lunsumio; Columvi; Polivy · BioOncology | $6,204 |
| Genentech USA, Inc. Aug 21, 2025 | Consulting Fee Lunsumio; Columvi; Polivy · BioOncology | $4,209 |
| Genentech USA, Inc. Dec 5, 2025 | Consulting Fee | $1,330 |
| Genentech USA, Inc. Dec 9, 2025 | Consulting Fee | $825 |
| Eli Lilly and Company Dec 15, 2025 | Consulting Fee JAYPIRCA · Oncology Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $800 |
| Genentech USA, Inc. Aug 20, 2025 | Travel and Lodging Lunsumio; Columvi; Polivy · BioOncology · travel to San Francisco, CA · in-kind | $554 |
| Genentech USA, Inc. Aug 20, 2025 | Travel and Lodging Lunsumio; Columvi; Polivy · BioOncology · travel to San Francisco, CA · in-kind | $474 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 61 industry-funded studies in 2025, from 21 companies. The companies reported $1,553,435 in research payments for these studies, mostly to the institutions running them.
- A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer
Exelixis Inc. - A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)
Novartis Pharmaceuticals Corporation - A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care in Participants With Stage I Adeno…
AstraZeneca Pharmaceuticals LP - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
AbbVie Inc. · Active, not recruiting · NCT05409066 - A phase 3b,randomized,multicenter,open label study to assess the efficacy of durvalumab plus tremelimumab versus pembrolizumab in combination with platinum based chemotherapy for first line treatment in mtastatic non …
AstraZeneca Pharmaceuticals LP - A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
AbbVie Inc. · Active, not recruiting · NCT05578976 - A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Rena…
Merck Sharp & Dohme LLC - An interventional openlabel randomized multicenter phase 3 study of PF07220060 plus fulvestrant compared to investigators choice of therapy in participants over 18 years of age with hormone receptorpositive HER2NEG…
Pfizer Inc. - Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma
Aveo Pharmaceuticals, Inc. · Completed · NCT04987203 - A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer mCRPC That Progressed On or After Prior Tr…
Merck Sharp & Dohme LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.